Researchers at the University of Massachusetts Medical School say they have come up with a new approach to characterize genetic variants associated with human disease. Their study (“Human Gene-Centered Transcription Factor Networks for Enhancers and Disease Variants”), published in Cell, will allow scientists to more easily and efficiently describe genomic variations underlying complex, multi-gene diseases, according to the researchers.
“Up to this point, we've only been able to investigate one disease-causing mutation at a time,” said principal investigator Marian Walhout, Ph.D., co-director of the program in systems biology and professor of molecular medicine at UMMS. “We now have a robust platform that allows us to interrogate hundreds of mutations in a single experiment. This will help us develop a map of the interactions that make up the networks that control gene expression and determine how mutations in the genome give rise to a variety of human diseases.”
An explosion in whole genome studies, often called genome-wide association studies or GWAS, was brought about by vast improvements in gene sequencing technology that has helped scientists locate thousands of genetic variations associated with hundreds of different diseases. Yet, as many as 90% of these mutations are found in areas of the genome that don't code for proteins, according to Dr. Walhout.
Mutations in transcription factors or their DNA binding sites can contribute to disease by disrupting gene regulation. This leads to too much, or not enough, of a target protein. A wide variety of diseases including cancer, neurological disorders, blood disorders, and metabolic diseases have been linked to aberrant gene regulation.
“Most of the disease-associated mutations these GWAS have identified don't actually change the protein itself, but are located in regulatory regions and could, therefore, change the levels of the protein,” added Juan Fuxman Bass, Ph.D., post-doctoral fellow and lead author of the Cell study. “The challenge for us has always been to identify how and why these mutations give rise to disease.
Using the enhanced, gene-centered yeast one-hybrid (eY1H) assays developed in 2011 by Dr. Walhout’s group, the researchers were able to perform thousands of experiments involving 1,000 transcription factors and more than 100 genetic variants. As a result, they were able to detect both loss and gain of interactions between DNA sites and transcription factors that were consistent with changes in gene expression that were found in the associated diseases.
“This work establishes eY1H assays as a powerful addition to the toolkit of mapping human GRNs [gene regulatory networks] and for the high-throughput characterization of genomic variants that are rapidly being identified by genome-wide association studies,” wrote the investigators.